P32/98, DPP IV Inhibitor, 10 MG

P32/98 is a potent and selective inhibitor of dipeptidyl peptidase IV (DPPIV) (K i =130nM). May be used in cell culture (1-10 mM) or in vivo (10 mg/Kg orally). Cell permeable. Experimentalanti-diabetic agent. Specific, competitive transition state substrate analog inhibitor of dipeptidyl peptidase IV (DPP-IV, DPIV, CD26, CD-26). Useful in diabetes research, as well as, protein preservation studies & transport. It was therefore hypothesized & validated that chronic DP IV inhibitor treatment of diabetic animals, in addition to improving glucose tolerance, would enhance β⁠-cell glucose responsiveness, replication, and turnover, and thus result in sustained improvements in β⁠-cell function 1 . P32/98 NHE3 (na + /h + exchangers) exists in multimeric complexes with dipeptidyl peptidase IV (DPPIV) in renal brush-border membranes. The possible role of DPPIV in modulating NHE3 activity was investigated. The goal was to determine whether specific competitive inhibitors that bind to the active site of DPPIV affect NHE3 activity in kidney proximal tubule cells. The findings suggested that the effect of DPPIV inhibitors to reduce NHE3 activity results from inhibition of a tyrosine kinase signaling pathway rather than by activation of PKA. We conclude that DPPIV plays an unexpected role in modulating Na + /H + exchange mediated by NHE3 in proximal tubule cells 2 . As previously stated, DPP IV inhibitors are a new class of anti diabetic drugs. However DPP IV metabolizes to at least 24 endogenous substrates, the pharmacological consequences of inhibiting the metabolism of most of these substrates is unknown. Research concluded that DPP IV is expressed in the renal microcirculation and inhibition of this ecto-enzyme causes arterial PYY1– 36 to more effectively enhance angiotensin II-induced renal vasoconstriction in genetically susceptible kidneys.

White powder